| Code | Product Name | Composition | Dosage Form | Administration Route | Container |
|---|---|---|---|---|---|
| 15-AF0-053 | Topotecan (as hydrochloride) | Topotecan (as hydrochloride) 1mg | Powder for solution for injection/infusion | Intravenous | Vial |
| 15-AF0-054 | Topotecan (as hydrochloride) | Topotecan (as hydrochloride) 4mg | Powder for solution for injection/infusion | Intravenous | Vial |
| 15-AF0-043 | Bevacizumab | Bevacizumab 100 mg | Concentrate for solution for injection/infusion | Intravenous | Vial |
| 15-AF0-044 | Bevacizumab | Bevacizumab 400 mg | Concentrate for solution for injection/infusion | Intravenous | Vial |
| 15-AF0-081 | Alymsys :Bevacizumab | Alymsys :Bevacizumab 400 mg | Concentrate for solution for injection/infusion | Intravenous | Vial |
| 15-AF0-073 | MVASI:Bevacizumab | MVASI:Bevacizumab 400 mg | Concentrate for solution for injection/infusion | Intravenous | Vial |
| 15-AF0-079 | Zirabev :Bevacizumab | Zirabev :Bevacizumab 400 mg | Concentrate for solution for injection/infusion | Intravenous | Vial |
| 15-AF0-084 | Stivant :Bevacizumab | Stivant :Bevacizumab 400 mg | Concentrate for solution for injection/infusion | Intravenous | Vial |
| 15-AF0-047 | Cetuximab | Cetuximab 5mg/ml | Solution for injection/infusion | Intravenous | Vial |
| 15-AF0-072 | Trastuzumab (Recombinant HER2) | Trastuzumab (Recombinant HER2) 600mg | Solution for injection | Subcutaneous | Vial |